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Abstract
Activating mutations of the epidermal growth factor receptor (EGFR) occur in multiple tumor types, including non–
small cell lung cancer (NSCLC) and malignant glioma, and have become targets for therapeutic intervention. The
determination of EGFR mutation status using a noninvasive, molecular imaging approach has the potential for
clinical utility. In this study, we investigated [11C]-erlotinib positron emission tomography (PET) imaging as a tool
to identify activating mutations of EGFR in both glioma and NSCLC xenografts. Radiotracer specific binding was
determined for high and low specific activity (SA) [11C]-erlotinib PET scans in mice bearing synchronous human
cancer xenografts with different EGFR expression profiles (PC9, HCC827, U87, U87 ΔEGFR, and SW620). Although
xenograft immunohistochemistry demonstrated constitutive EGFR phosphorylation, PET scan analysis using the
Simplified Reference Tissue Model showed that only kinase domain mutant NSCLC (HCC827 and PC9) had signif-
icantly greater binding potentials in high versus low SA scans. Xenografts with undetectable EGFR expression
(SW620), possessing wild-type EGFR (U87), and expressing an activating extracellular domain mutation (U87
ΔEGFR) were indistinguishable under both high and low SA scan conditions. The results suggest that [11C]-erlotinib
is a promising radiotracer that could provide a novel clinical methodology for assessing EGFR and erlotinib inter-
actions in patients with tumors that harbor EGFR-activating kinase domain mutations.
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Introduction
The epidermal growth factor receptor (EGFR) is a transmembrane
glycoprotein commonly overexpressed by malignant tumors. Ligand
stimulation of the EGFR extracellular domain causes receptor dimer-
ization, activates the intracellular kinase domain, and drives down-
stream signal transduction cascades that promote proliferation,
migration, angiogenesis, and survival. In addition to ligand-induced
activation, genetic mutation or deletion also produces constitutively
active forms of the receptor that drive tumor signaling [1,2]. In
malignant glioma, in-frame deletion of EGFR exons 2 to 7 removes
extracellular domain constraints for receptor activation and is found
in 40% of patients [3]. In non–small cell lung cancer (NSCLC),
tyrosine kinase domain deletions (or point mutations) increase kinase
activity and are found in 10% to 15% and up to 50% of Western
and Asian populations, respectively [4,5]. The relative frequency of
activating EGFR mutations found in tumors along with the central
role of EGFR in stimulating cell signaling have therefore identified
this receptor as a therapeutic target in oncology.
Successful EGFR targeting has been achieved clinically with either
receptor-specific antibodies such as cetuximab [6], which depletes EGFR
Address all correspondence to: Joseph N. Contessa, MD, PhD, PO Box 208040,
333 Cedar Street, New Haven, CT 06520-8040. E-mail: joseph.contessa@yale.edu
1This work was supported by a grant from the Yale Clinical Center for Investigation
Scholar Award (UL1RR024139/KL2RR024138) to J.N.C., the Kalimeris fund,
and support from the Yale PET Center. J.R.P. is supported by the National Science
Foundation Graduate Research Fellowship under grant DGE-1122492. Any opinion,
findings, and conclusions or recommendations expressed in this material are those of the
authors(s) and do not necessarily reflect the views of the National Science Foundation.
Received 18 September 2013; Revised 7 November 2013; Accepted 10 November 2013
Copyright © 2013 Neoplasia Press, Inc. All rights reserved 1522-8002/13/$25.00
DOI 10.1593/neo.131666
www.neoplasia.com
Volume 15 Number 12 December 2013 pp. 1347–1353 1347
from the cell surface, or small molecule tyrosine kinase inhibitors
(TKIs) such as gefitinib and erlotinib, which are ATP-competitive
inhibitors of the kinase domain active site [7]. Both antibody and
TKI-based EGFR-specific therapies have been exploited and adapted
as potential imaging agents in the diagnosis and management of
patients with malignant tumors [8–10]. Recently, EGFR TKIs with
either reversible or irreversible binding characteristics have been radio-
labeled and investigated as potential radiotracers in animal models
[11–13]. Of these tracers, the most promising appears to be [11C]-
erlotinib, which has a structure identical to the clinically used drug.
This tracer has been advanced to clinical investigations in patients
with NSCLC and has been proposed to detect tumors bearing EGFR
mutations [14,15].
Although preliminary work on this positron emission tomography
(PET) imaging strategy is encouraging, the extent to which [11C]-erlotinib
can be used to image tumors with activated EGFR remains undefined.
In addition, the optimal method for kinetic modeling and image anal-
ysis for [11C]-erlotinib PET also requires further investigation. In the
present report, we tested the ability of [11C]-erlotinib to selectively detect
EGFR expression inmouse tumor xenograft models. UsingNSCLC and
glioma xenografts expressing different EGFR-activating gene mutations,
we performed kinetic modeling analysis using the Simplified Reference
Tissue Model (SRTM) under conditions of both high and low specific
activities of the radiotracer. Our analysis and quantitative comparisons
of PET scans between NSCLC and glioma xenografts suggest that
[11C]-erlotinib imaging provides a noninvasive method for determining
the density of kinase domain mutant EGFR expression in tumors.
Materials and Methods
Western Blot Analysis
Western blots were performed by standardmethods. The C-terminal
EGFR antibody was purchased from Santa Cruz Biotechnology (Santa
Cruz, CA; SC-03). EGF was purchased from Biomedical Technologies
(Stoughton, MA) and used to stimulate cells for 10 minutes at a final
concentration of 10 ng/ml.
Xenografts and Immunohistochemistry
Xenografts were initiated in athymic, nude-Foxn1nu mice (Harlan,
South Easton, MA) by subcutaneous injection of 1 × 107 cells in the
flank or shoulder. The SW620 cell line was purchased from American
Tissue Culture Collection (ATCC, Manassas, VA). The PC9 and
HCC827 cell lines were gifts from Katie Politi (Yale University,
New Haven, CT) and Jeff Engelman (Harvard Medical School,
Boston, MA), respectively. The U87 control and U87 ΔEGFR (EGFR
VIII expression) cell lines were a gift fromWebster Cavanee (University
of California, San Diego, CA). Tumors were grown over 10 to 14 days
until a maximal dimension of ∼1.0 cm for PET imaging is reached. For
immunohistochemistry (IHC), xenografts were dissected and fixed in
formalin-buffered saline for 24 hours followed by 70% ethanol before
paraffin embedding. Tumor sections were deparaffinized and rehy-
drated in distilled water with 3% hydrogen peroxide to block endoge-
nous peroxidase. Antigenic sites were exposed using Proteinase K.
Primary antibody incubation was then performed for 30 minutes fol-
lowed by incubation with secondary antibody conjugates. The primary
EGFR antibody (clone 111.5) recognizing the extracellular domain was
from Thermo Fisher Scientific (Lafayette, CO), and the EGFR Y1173–
specific antibody was from Cell Signaling Technology (Danvers, MA).
Immunoreactivitywas then detectedwithHRP-conjugated secondary anti-
bodies using Envision+ and DAB (Dako, Carpenteria, CA). Slides were
subsequently counterstained with hematoxylin and permanently cover-
slipped in resin mounting media.
[11C]-Erlotinib Synthesis
Radiosynthesis of [11C]-erlotinib was carried out with a labeling
method similar to that reported previously [9]. In brief, 1 to 5 mg of
6-O-desmethyl-erlotinib was dissolved in N ,N -dimethylformamide
(0.3 ml) and mixed with sodium hydride. The solution was degassed
with argon for 5 minutes before bubbling with [11C]-methyl iodide
generated from [11C]-CO2 in a General Electric FX MeI module.
The resulting solution was heated at 120°C for 5 minutes, diluted with
the semi-preparative HPLCmobile phase (1.5 ml), and loaded onto the
HPLC column (Phenomenex Luna C18, 10 μm, 10 × 250 mm). The
column was eluted with a mixture of 45% acetonitrile and 55% 0.1 M
ammonium acetate with 0.1% acetic acid (pH = 5.5), at a flow rate of
5 ml/min. The desired product fraction (eluting at 15-16 minutes)
was collected, diluted with water (50 ml), and passed through a C18
SepPak cartridge (Waters, Milford, MA). The cartridge was rinsed
with 0.001 N HCl (10 ml). The radioactive product, trapped on the
SepPak, was recovered by elution with 1 ml of United States Pharma-
copeial (USP) Convention absolute ethanol, followed by 3 ml of USP
saline, into a product vial containing 7 ml of USP saline and 40 μl of
USP 4.2% NaH2CO3 solution. This mixture was then passed through
a sterilemembrane filter (0.22 μm) for terminal sterilization and collected
in an empty sterile vial to afford a formulated solution ready for injection.
Radiochemical purity of the final product was >99%, and the specific
activity (SA) was 4.3 ± 1.3 mCi/nmol (n = 9) at the end of synthesis.
Identity of the product was confirmed by co-elution of the radio-
active product with an authentic reference standard, as determined by
HPLC analysis (Column: Luna, C18, 5 μm, 4.6 × 250 mm; mobile
phase: mixture of 42% acetonitrile and 58% 0.1 M ammonium
acetate with 0.1% acetic acid, pH = 5.5; flow rate = 2 ml/min). The
retention time for [11C] erlotinib was ∼7.5 minutes.
[11C]-Erlotinib PET Scans
Mice bearing xenografts were anesthetized with inhaled isoflurane
(2%) throughout the course of image acquisition. The mice were
imaged in pairs with torsos positioned in the scanner’s field of view
to optimize resolution of the flanks and shoulders. A 100-W heating
lamp was positioned above the scan bed to maintain body tempera-
ture. Mice were imaged with a Siemens Focus 220 PET scanner,
which has a spatial resolution of 1.4 mm at the field of view center.
Before imaging, a computed tomography (CT) transmission scan
using a rotating Cobalt-57 point source was performed for attenua-
tion correction and to establish mouse orientation. Image acquisition
was initiated immediately after delivery of a retro-orbital sinus injec-
tion of the tracer. High SA scans delivered [11C]-erlotinib at an
activity of 0.16 ± 0.12 mCi and mass of 9.31 ± 5.16 nmol. Low
SA scans, where unlabeled erlotinib (10 mg/kg; 465 μmol) was com-
bined with the [11C]-erlotinib tracer, had an injected activity of 0.06 ±
0.03 mCi. Low SA scans were performed on the same day 4 hours
(>10 half-lives) after the high SA scans. During emission scans, three-
dimensional (3D) data were acquired in list mode for up to 120 min-
utes and Fourier rebinned as two-dimensional (2D) sinograms with
time frames of 7 × 30 seconds, 5 × 90 seconds, and 21 × 300 seconds.
Dynamic images were reconstructed with ordered subset expectation
maximization at a voxel size of 0.949 × 0.949 × 0.796 mm. Correc-
tions for attenuation, scatter, dead time, detector sensitivity, and
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randoms were applied to emission data. Images were reconstructed in
volumes of 256 × 256 × 95 voxels.
Kinetic Modeling
Regions of interest (ROIs) for xenografts were manually drawn
using anatomic location and summed images for late (95-120 min-
utes) or total (0-120 minutes) [11C]-erlotinib PET scans. In larger
tumors, round central areas devoid of tracer uptake were thought to
be consistent with tumor necrosis and were excluded from analysis.
[11C]-erlotinib time-activity curves (TACs) were generated for each
ROI by averaging voxel intensity at each time point. TACs are given
in units of radioactivity concentration. For the purpose of display, we
used standard uptake value (SUV) units. That is, we normalized the
TACs by the injected activity per body weight so that curves from
different animals could be properly displayed on one scale. The
SRTM [16] was used to fit the TACs of each region, and the shoulder
muscle without a xenograft was used as the reference region. SRTM
fitting of TACs yielded an estimate of non-displaceable binding
potential (BPND, abbreviated here as BP), perfusion rate (R1), and
efflux rate constant (k2a) in the ROI. BP is the primary parameter
of interest as it approximates the steady-state ratio of free to bound
tracer in the tissue. BP also depicts the ratio of available receptors
(Bavail) to the tracer’s affinity for the receptors (K d). R1 describes
the regional tracer delivery to the ROI relative to the reference region.
The [11C]-erlotinib BP was averaged, and comparisons were made
across xenograft types (e.g., PC9 vs HCC827) or SA conditions (e.g.,
high SA vs low SA). As an alternate end point, SUV was calculated for
each ROI and condition by averaging the TAC values in SUV units
from the first 90 minutes. All statistical comparisons were made using
the Student’s t test (one-tailed). Comparisons with P < .05 were
considered to be statistically significant.
Results
EGFR Phosphorylation in Tumor Xenograft Models
We used both lung and glioma xenograft tumor models to inves-
tigate [11C]-erlotinib imaging of EGFR-activating mutations in vivo.
Xenografts were first evaluated for EGFR activation with IHC using
Figure 1. Xenograft tumor models for [11C]-erlotinib PET imaging. (A) Xenograft IHC using EGFR and tyrosine (Y) 1173 phosphorylation-
specific antibodies. Representative images from colon cancer–derived (SW620) and NSCLC-derived (HCC827 and PC9) xenografts are
shown. (B) IHC of EGFR-phosphorylated Y1173 in U87 glioma xenografts with and without expression of the extracellular domain–
truncated ΔEGFR. (C) Western blot analysis demonstrating constitutive or EGF-induced EGFR Y1173 phosphorylation in U87 cell lines.
Figure 2. [11C]-erlotinib imaging of a mouse bearing bilateral HCC827 and PC9 bilateral flank xenografts. (A) Transmission scan of
the mouse used to gain anatomic information for ROI placement. (B) [11C]-erlotinib PET early time image summed from 0 to 10 minutes.
PET images are smoothed with a 1.0-mm3 kernel for illustrative purposes. (C) [11C]-erlotinib PET late time image summed from 95 to
120 minutes. (D) ROIs (blue) corresponding to flank xenograft location used for data acquisition and TAC analysis.
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an EGFR-specific antibody that recognizes phosphorylation of tyro-
sine 1173 (Y1173), a primary EGFR auto-phosphorylation site.
HCC827 and PC9 NSCLC xenografts, both containing in-frame
EGFR kinase domain deletions (E746-A750), displayed high levels
of phospho-Y1173 immunoreactivity consistent with receptor activa-
tion (Figure 1A). In contrast, the SW620 colon cancer cell line,
which has virtually undetectable levels of EGFR, had no phospho-
Y1173 immunoreactivity. The control U87 glioma and ΔEGFR-
expressing U87 glioma xenografts were also analyzed by IHC
(Figure 1B). The ΔEGFR-expressing U87 xenografts showed a high
level of EGFR Y1173 phosphorylation compared to the low level
seen in control U87 tumors. These results are consistent with in vitro
experiments using these cell lines, which demonstrate high levels of
constitutive ΔEGFR Y1173 phosphorylation and low but EGF-
inducible Y1173 phosphorylation of the endogenous, wild-type recep-
tor (Figure 1C ). These IHC experiments demonstrate EGFR activation
in HCC827 and PC9 NSCLC as well as ΔEGFR-expressing U87
xenograft model systems.
[11C]-Erlotinib PET Imaging
[11C]-erlotinib PET imaging was performed as described inMaterials
and Methods section. Examples of a transmission scan (Figure 2A)
and summed PET images (Figure 2, B and C ) used to define the
anatomic locations of xenografts for ROI definitions (Figure 2D) are
presented. ROI parameters for data acquisition are presented in Table 1
for scans with both high and low SA images in planes containing the
xenografts, and the reference ROIs demonstrate considerable [11C]-
erlotinib accumulation at the site of flank xenografts as well as a central
accumulation of the tracer within the mouse. The latter finding cor-
responds to hepatic metabolism and gastrointestinal tract excretion of
erlotinib [17,18].
[11C]-Erlotinib Selectivity
To evaluate the selectivity of [11C]-erlotinib for imaging EGFR-
activating mutations, TACs were generated for each xenograft type
using both high and low SA tracer preparations. Sample TACs for
a mouse bearing synchronous HCC827 and PC9 NSCLC xenografts
show sustained accumulation of tracer over time in the high SA con-
dition (Figure 3A). HCC827 xenografts show quantitatively higher
tracer concentrations than PC9 xenografts for comparable doses. In
Table 1. [11C]-Erlotinib Tumor Imaging and Data Acquisition Parameters for Both High and
Low SA Conditions.
Xenograft EGFR Properties SA n Voxels R1 BP SUV
SW620 WT* High 1 100 n/a 1 n/a −1 n/a 0.28 n/a
HCC827 Exon 19 del
(E746-A750)
3 168 (13) 1.12 (0.22) 6.38 (1.90) 0.91 (0.60)
PC9 Exon 19 del
(E746-A750)
3 82 (50) 0.787 (0.27) 2.45 (1.72) 0.45 (0.31)
U87 WT 3 102 (16) 1.3 (0.07) −0.69 (0.53) 0.51 (0.56)
U87Δ ΔEGFR 3 124 (23) 0.23 (0.08) −0.13 (0.20) 0.46 (0.29)
SW620 WT* Low 1 42 n/a 1.24 n/a −1 n/a 0.08 n/a
HCC827 Exon 19 del
(E746-A750)
3 153 (57) 0.49 (0.35) 0.38 (0.27) 0.93 (1.33)
PC9 Exon 19 del
(E746-A750)
3 72 (49) 0.53 (0.53) 0.12 (0.40) 0.48 (0.67)
U87 WT 2 100 (25) 1.75 (0.58) −0.43 (0.81) 0.33 (0.30)
U87Δ ΔEGFR 2 106 (62) 0.57 (0.27) 0.16 (0.79) 0.24 (0.16)
The mean number of voxels per ROI is reported along with SRTM calculated parameters and
SUVs calculated at 90 minutes. Average R1 and BP values are used to quantify delivery of
[11C]-erlotinib and receptor density, respectively. All values are shown as an average across sample
size n with the SD in parentheses.
*The WT EGFR of SW620 is not expressed at detectable levels.
Figure 3. [11C]-erlotinib TACs in mice bearing multiple tumor xenografts for mice imaged under high (A and B) or low (C and D) SA
conditions. TACs for HCC827 (squares), PC9 (diamonds), and SW620 (triangles) or U87 (asterisks) and U87Δ (closed circles) xenografts
with muscle (open circles) used as reference. Data points are SUVs with SD, and overlaid lines depict SRTM curve fits.
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contrast, the SW620 xenograft shows only an initial uptake of tracer
followed by a washout phase that begins approximately 20 minutes
into the scan. This pattern of rapid uptake and washout was identical
to the muscle TAC (the curves are superimposable on Figure 3A). In
contrast to the high SA scans, scans with concurrent administration
of excess unlabeled erlotinib (“low SA scans”) did not display pro-
longed tissue uptake over time or appreciable differences between
any of the xenografts and the reference ROI (Figure 3C ).
In PET imaging experiments performed with U87 glioma xeno-
grafts, specific [11C]-erlotinib tracer uptake was not observed irre-
spective of ΔEGFR expression (Figure 3B). The early increase in
tracer uptake (0-20 minutes) in tumor was not different from the
reference ROI, and the same pattern for all curves was seen in low
SA imaging experiments (Figure 3D) as well. Together, these data
suggested that [11C]-erlotinib accumulates in NSCLC tumors with
activating kinase domain mutations but does not accumulate in glio-
mas with an extracellular domain–activating mutation. Further kinetic
modeling was therefore performed.
[11C]-Erlotinib Kinetic Modeling
TACs for each xenograft type were generated and fit according to
the SRTM to estimate [11C]-erlotinib BPs for each tumor type. The
calculated BP values are presented graphically in Figure 4 for both
high and low SA scan conditions. For high SA conditions, the
HCC827 and PC9 NSCLC xenografts had the highest BP values:
6.38 (±1.9) and 2.45 (±1.72), respectively. HCC827 BP values were
significantly greater in the high SA scans than in low SA scans (P <
.02). Differences between high SA and low SA BPs for PC9 trended
toward significance (P = .075). BP values of HCC827 (high SA) were
also significantly greater than those for PC9 (P < .03). There was no
significant difference in BP estimates for U87, U87ΔEGFR, or SW620
xenografts demonstrating the absence of selective [11C]-erlotinib
accumulation in these tumor types.
Discussion
Small molecule inhibitors of protein kinases, enzymes that drive sur-
vival signaling in tumors, are a relatively new class of therapeutics
that have been developed in oncology over the past two decades. The
sheer number and availability of these targeted inhibitors have provided
considerable opportunity for exploring their utility as molecular imag-
ing agents. In the present work, we investigated the potential for imag-
ing the biology of EGFR using 11C-labeled erlotinib, an EGFR-specific
TKI. [11C]-erlotinib PET imaging was tested in xenograft tumor mod-
els expressing common EGFR mutations that cause receptor activation
and signaling. Our results demonstrate that [11C]-erlotinib binds to a
target in xenografts expressing EGFR with kinase domain mutations
but does not bind in those bearing an activating mutation in the extra-
cellular domain (ΔEGFR). Further modeling of dynamic PET data
using SRTM, a standard kinetic model of tracer uptake, demonstrated
significant amounts of specific tracer binding to xenografts containing
kinase domain mutant EGFR. This finding is important as it suggests
that [11C]-erlotinib PET images show the density of one type of mutant
receptors expressed in a tumor. Together, these data support the valid-
ity of this new molecular imaging tool and provide mechanistic insights
for the clinical implementation of [11C]-erlotinib for tumor imaging.
[11C]-erlotinib PET scans of NSCLC and glioma xenograft tumors
only demonstrated specific radiotracer binding in NSCLC xenografts.
Although EGFR is active and expressed at high levels in the U87
ΔEGFR cell line, we were not able to detect specific binding of the
tracer. Instead, [11C]-erlotinib PET results for U87 ΔEGFR were
similar to those of control U87 xenografts that express only the
endogenous, wild-type receptor. The discrepant results between EGFR
mutants expressed in NSCLC tumors versusmalignant gliomas are best
explained by the nature of NSCLC EGFR kinase domain mutations,
which have increased affinities for ATP-competitive small molecule
inhibitors [19,20]. Our data strongly suggest that the selectivity of
[11C]-erlotinib imaging for NSCLC xenografts is independent of
wild-type EGFR expression or activation and is instead dependent on
the molecular and biophysical alteration caused by EGFR kinase
domain mutations.
EGFR is a prototypical receptor tyrosine kinase implicated in
tumorigenesis, proliferation, and survival signaling and has served
as a model for kinase targeting and the development of novel thera-
peutics. However, because the utility of [11C]-erlotinib PET appears
to be limited to detection of mutant EGFR with increased inhibitor
affinity, kinase inhibitor radiolabeling may not be a generally appli-
cable approach for imaging other clinically relevant kinases. We pre-
dict, for example, that radiolabeled kinase inhibitors would not be
suitable for imaging other types of kinase activating mutations that
do not change receptor affinity, such as those seen with Kit in gastro-
intestinal stromal tumors [21]. Furthermore, reversible kinase inhibi-
tors are likely to be poor imaging agents for kinase domain–intact
Figure 4. Average BP of [11C]-erlotinib determined by SRTM in both high SA (black) and low SA (white) conditions. (A) Comparison of
average BPs for SW620, HCC827, and PC9 xenografts. (B) Average BPs for U87 and U87 ΔEGFR tumors. Error bars represent the SD.
Significant differences are reported in Results section.
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receptors such as the fibroblast growth factor receptor and ErbB2
that are amplified and overexpressed in 15% of squamous NSCLC
and 30% of breast cancers, respectively. New PET imaging strate-
gies to image the amplification of EGFR or other protein kinases
will thus require an approach that exploits the differential expres-
sion levels between tumors and normal tissues, such as the investi-
gation of irreversible kinase inhibitors [22,23] or through the design
of high affinity and mutation-specific kinase inhibitors [24] as
PET radiotracers.
A major advantage of our experimental design is the use of syn-
chronous flank xenografts. This approach reduced animal-specific
variability in tracer bioavailability and metabolism, which often con-
found interanimal comparisons. Furthermore, our experiments were
performed in both high and low SA conditions. In the low SA con-
dition, excess unlabeled erlotinib leads to a measure of nonspecific
(“non-displaceable”) tracer uptake only. Recently, Bahce et al. empha-
sized the need for low SA studies to confirm their clinical observa-
tions of [11C]-erlotinib uptake by NSCLC tumors [15], because
performing both high and low SA injections in patients is impractical.
Thus, our animal experiments take on even higher significance by
demonstrating both [11C]-erlotinib selectivity for EGFR-mutant
NSCLC and receptor-mediated binding through the comparison
between high SA (tracer) and low SA (blocking) studies. Our study
design also facilitates comparisons between HCC827 and PC9 xeno-
grafts, where a significant difference in BP between the two tumor
types was observed. Because the two NSCLC xenografts express iden-
tical EGFR kinase domain deletions (E746-A750), we assume that
the affinity of the tracer for the receptor is the same in each tumor.
Thus, differences in BP between the NSCLC tumor types can be
interpreted to reflect unequal levels of expression of mutant EGFR.
The results from IHC presented herein as well as DNA copy number
analysis demonstrating greater gene amplification and protein expres-
sion in HCC827 versus PC9 provide additional support for this
interpretation [2,25].
The use of the SRTM leads to estimation of BP without the need
for arterial blood sampling. However, SRTM must be applied with
care as it assumes that the reference region differs only in its lack of
binding sites for the tracer and is otherwise identical to the target
region. Said another way, the nonspecific volume of distribution is
assumed to be the same in the target and reference. In our experi-
ments, we initially used a synchronous SW620 xenograft, a tumor
with no detectable EGFR expression, as the preferred reference tissue.
However, once subsequent analysis using the shoulder muscle as a
reference was found to be comparable to that using SW620, the easier
approach using healthy muscle as a reference was adopted. SRTM also
neglects vascular-borne activity in the target and reference tissues [16].
As we anticipate human imaging, we must keep in mind that differ-
ential vascular growth between tumors and healthy normal tissue may
lead to biases in SRTM-based estimates of BP. It will be necessary to
validate the use of SRTM against models using arterial- or image-
derived input functions [15]. Provided that assumptions of the model
are met and biases are minimal, it is always preferable to estimate BP
rather than simply SUV. Whereas SUV makes no distinction between
nonspecific versus specific (receptor-mediated) uptake, BP is a measure
of the latter only. Thus, BP will be more sensitive than SUV to differ-
ences in expression level of the target (i.e., differences in receptor den-
sity). This advantage is reflected in the statistical significance of the
difference in BP values across tumor types but lack of significance when
looking at SUV.
Further clinical experiments to validate [11C]-erlotinib as a sen-
sitive radiotracer to detect kinase domain mutations of the EGFR
are required, but our results strongly suggest that this tracer may
present applications for the management of patients with NSCLC.
Notwithstanding the greater convenience of a tracer labeled with
fluorine-18 for use in the clinic, [11C]-erlotinib PET could be a useful
diagnostic tool for select patients undergoing surveillance of enlarging
lung nodules that are negative on fluorodeoxyglucose (FDG)-PET or
those patients unable to undergo standard biopsy because of risks
associated with the procedure. In addition, [11C]-erlotinib PET
may provide clinically relevant information that complements molec-
ular pathology analyses by simultaneous quantification of kinase
domain mutation density at multiple involved or metastatic sites.
The predicted and reported absence [10] of selective tracer accumu-
lation for labeled erlotinib analogs with T790Mmutations (secondary
EGFR kinase domain mutations that mediate therapeutic resistance
by decreasing affinity for erlotinib) suggests that this EGFR imaging
strategy could detect either primary or acquired resistance to EGFR
inhibitors. In the clinic, [11C]-erlotinib PET has the potential to
define anatomic sites of resistance and even alter treatment recom-
mendations. However, we recognize that [11C]-erlotinib does have
anatomic limitations, as demonstrated in our study by hepatic metab-
olism and gastrointestinal excretion of the tracer, which would limit
its use in imaging tumors in these sites.
In summary, we have performed [11C]-erlotinib PET imaging in
NSCLC and glioma xenografts and found specific binding of the
tracer for activating mutations of the kinase domain but no specific
binding for activating mutations of the extracellular domain of the
EGFR. Together, our work further characterizes the mechanistic
basis for translation of this PET imaging modality for clinical use.
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